Robert H. Lurie Comprehensive Cancer Center of Northwestern University Northwestern Medicine | Strategic Alliance Partners

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Hematologist-oncologists discuss the risk stratification of patients with myelodysplastic syndromes and how patient risk status determines prognosis.

A panel of experts on myelodysplastic syndromes (MDS) introduce themselves and provide an overview of diagnosis practices, highlighting common symptoms and the typical patient presentation.

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

The transmembrane protein B7-H4 has emerged as an interesting therapeutic target in multiple solid tumors, with investigators mostly focusing on the development of antibody-drug conjugates aimed at the pathway.

A new artificial intelligence tool may make it possible to spare breast cancer patients unnecessary chemotherapy treatments by using a more precise method of predicting their outcomes.

Seema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.

Priya U. Kumthekar, MD, details the specialized program for fellows while reflecting on her own experiences, highlights her research in brain metastases, and offers advice to both fellowship directors and current fellows in oncology.

The Northwestern Medicine Canning Thoracic Institute Hispanic Program was recently launched to offer personalized care for lung and thoracic patients in their native language, making life-saving care more accessible for the Hispanic community and people who prefer to speak Spanish by removing cultural and linguistic barriers.

Scientists develop ‘QR code for cancer cells,’ like tagging swans in a pond.

Northwestern Medicine scientists report results of the first in-human clinical trial in which they used a novel, skull-implantable ultrasound device to open the blood-brain barrier and repeatedly permeate large, critical regions of the human brain to deliver chemotherapy that was injected intravenously.

A panel of skin cancer experts offer closing thoughts on intralesional therapy for treating melanoma and CSCC.

For the second time at Northwestern Medicine, surgeons have successfully performed a double-lung transplant on a patient with stage 4 lung cancer who was being considered for hospice.

An expert panel discusses the use of tumor-directed oncolytic therapies for melanoma and cutaneous squamous cell carcinoma.

A comprehensive overview of treatment approaches for patients with high-risk melanoma.

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

Expert oncologists look to the future of treatment for cutaneous squamous cell carcinoma.

Skin cancer expert Anna C. Pavlick, DO, discusses treatment duration approaches for cutaneous squamous cell carcinoma.

Nikhil Khushalani, MD, gives a comprehensive overview of cemiplimab and pembrolizumab for treating CSCC.

Anna C. Pavlick, DO, overviews systemic therapy options for patients with unresectable or metastatic CSCC.

Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.

Skin cancer experts discuss prognosis and unmet needs in the cutaneous squamous cell carcinoma and melanoma treatment spaces.

Emma L. Barber, MD, discusses how key data from the phase 3 KEYNOTE-775 study improved the identification of patient populations within endometrial cancer that benefit from second-line immunotherapy.

A panel of skin cancer experts give an overview of cutaneous squamous cell carcinoma and melanoma.

Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.

Maha H. Hussain, MD, FASCO, FACP, discusses key efficacy and safety data from a secondary analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer.

Emma L. Barber, MD, discusses the role of molecular profiling for treatment considerations in patients with endometrial cancer.